Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2017

Summary

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. 

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 5 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Bladder Cancer, Melanoma, Renal Cell Carcinoma, Atopic Dermatitis, Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Hematological Tumor, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis. 

The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview 7
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 13
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development 23
Abeome Corp 23
Alligator Bioscience AB 23
Apogenix GmbH 24
BioInvent International AB 24
Bristol-Myers Squibb Company 25
Denceptor Therapeutics Ltd 25
Enumeral Biomedical Holdings Inc 26
GlaxoSmithKline Plc 26
Glenmark Pharmaceuticals Ltd 27
Incyte Corp 27
Kyowa Hakko Kirin Co Ltd 28
MedImmune LLC 28
Pfizer Inc 29
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles 30
ATOR-1015 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BMS-986178 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
durvalumab + MEDI-0562 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ENUM-004 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GBR-8383 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
GSK-3174998 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
INCAGN-1949 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
KHK-4083 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MEDI-0562 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MEDI-0562 + tremelimumab - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibody to Agonize OX40L Receptor for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
PF-04518600 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Recombinant Protein to Agonize OX40 for Solid Tumor - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ZL-1101 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products 49
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products 50
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones 51
Featured News & Press Releases 51
Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015 51
May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015 51
Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 51
Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 52
Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors 52
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 53
Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment 53
Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by Abeome Corp, H2 2017 23
Pipeline by Alligator Bioscience AB, H2 2017 23
Pipeline by Apogenix GmbH, H2 2017 24
Pipeline by BioInvent International AB, H2 2017 24
Pipeline by Bristol-Myers Squibb Company, H2 2017 25
Pipeline by Denceptor Therapeutics Ltd, H2 2017 25
Pipeline by Enumeral Biomedical Holdings Inc, H2 2017 26
Pipeline by GlaxoSmithKline Plc, H2 2017 26
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 27
Pipeline by Incyte Corp, H2 2017 27
Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 28
Pipeline by MedImmune LLC, H2 2017 28
Pipeline by Pfizer Inc, H2 2017 29
Dormant Projects, H2 2017 49
Discontinued Products, H2 2017 50